Invasive mold infections are a potentially lethal complication in patients receiving allogeneic hematopoietic SCT (alloHSCT) and have a major impact on morbidity and mortality. Cumulative incidences of invasive aspergillosis range up to 7% in patients with alloHSCT. 1 Cerebral aspergillosis carries particularly a poor prognosis. In a recent analysis of patients with invasive aspergillosis after alloHSCT, 14 (42%) of 33 patients had central nervous system (CNS) involvement. None of these 14 patients with cerebral aspergillosis responded to amphotericin B therapy and all patients experienced rapid deterioration. The mortality was 100% and the median survival from the onset of symptoms or signs of cerebral aspergillosis was only 7 days. 1 Penetration of amphotericin B, itraconazole and echinocandins into the CNS is low to negligible, whereas voriconazole penetrates well into the CNS. 2, 3 In a recent retrospective analysis, improved response (35%) and survival (31%) rates were observed in 81 patients treated with voriconazole for cerebral aspergillosis. 4 Posaconazole is a new triazole with broad activity against various fungi, including Aspergillus species and Zygomycetes, and has recently gained approval for antifungal prophylaxis in patients with alloHSCT and GVHD. 5 In addition, posaconazole exhibits activity in various CNS fungal diseases, including cerebral zygomycosis. 6 However, limited CNS pharmacokinetic data on posaconazole are available. Cerebrospinal fluid (CSF) concentrations of posaconazole were found to be less than 50 ng/ml in a rabbit model with cryptococcal meningitis. 7 In a recent report, posaconazole CSF concentrations ranged from 153 to 221 ng/ml in two patients and were undetectable in another patient. 8 In October 2007, a 23-year-old male patient with meningeal and systemic relapse of acute myeloid leukemia underwent a second alloHSCT from an unrelated, matched donor using a reduced-intensity conditioning regimen (fludarabine 150 mg/m 2 , melphalan 140 mg/m 2 ). The post transplant period was complicated by an invasive, pulmonary aspergillosis, which was initially treated with caspofungin (70 mg loading dose, followed by 50 mg daily) and subsequently with a combination of caspofungin and voriconazole (day 1: 400 mg b.i. . Liposomal cytarabine (50 mg) was repeatedly given intrathecally, starting 22 weeks after transplantation, to prevent meningeal relapse of the acute leukemia. Informed consent was obtained from the patient to assay posaconazole concentrations in paired plasma and CSF specimens, which were drawn during diagnostic spinal tap or intrathecal administrations of liposomal cytarabine. Samples were analyzed by combined high-performance liquid chromatography/mass spectroscopy with a lower limit of detection for posaconazole of 10 ng/ml (plasma) and 0.5 ng/ml (CSF).
Oral doses of 400 mg posaconazole were administered 15 min after oral intake of 200 ml nutritional supplement (fat content 29.5%). Overall, six paired plasma and CSF samples were obtained 75-135 min (median 90 min) after drug administration on days 10, 21, 23, 27, 30 and 36 of the posaconazole therapy. Concentrations of posaconazole ranged from 136 to 989 ng/ml (median 294 ng/ml) in plasma and 1.2-4.6 ng/ml (median 1.5 ng/ml) in CSF. The ratios of posaconazole CSF to plasma concentrations were always less than 0.009 (Table 1) .
In our patient, CSF concentrations of posaconazole were low and would unlikely be effective in CNS fungal diseases. Although our patient had no signs of intestinal GVHD and, to enhance bioavailability of posaconazole, nutritional supplement with high fat content was given, the mean posaconzole plasma level was lower than that reported earlier in patients after alloHSCT (395 ng/ml vs Z958 ng/ml). 5 However, we observed remarkably low ratios of CSF to plasma posaconazole concentrations, suggesting that higher plasma drug concentrations would have minor effects on CSF drug concentrations in this particular patient. In contrast, substantial higher posaconazole CSF concentrations (153-221 ng/ml) with CSF/plasma ratios ranging from 0.4 to 2.3 were recently reported in two patients. 8 Both these patients had CNS infections (one bacterial meningitis with Aspergillus abscess/ventriculitis, one bacterial brain abscess) suggesting that inflammatory disruption of the blood-brain barrier could promote CNS penetration of posaconazole. It is noted that posaconazole CSF concentrations were undetectable (o10 ng/ml) in another patient from this report and this patient had fungal sinusitis without evidence of a CNS infection. 8 In general, substances may penetrate more easily into the CSF compared with brain tissue, as the blood-CSF barrier mainly consists of a fenestrated epithelium, whereas the epithelium at the blood-brain barrier is connected with tight junctions. 9 Interestingly, reported concentrations of voriconazole in brain tissue exceed those in CSF, indicating brain tissue accumulation. 3 Posaconazole is a lipophilic molecule, which favors enrichment in brain tissue, but brain tissue levels of posaconazole have not yet been reported. Pretreatment with liposomal cytarabine, which frequently causes arachnoiditis, might have contributed to the observed limited CSF penetration, but our patient never showed signs or symptoms of arachnoiditis. Penetration of lipophilic substances with a MW greater than 600 Da into the CNS is limited. 9 Thus, the pronounced lipophilicity of posaconazole favors CNS penetration, but rather high MW of this triazole (708 Da) makes penetration across the blood-brain barrier less likely. Itraconazole is another lipophilic triazole with a similar MW (705 Da), which poorly penetrates into the CNS. 2 Animal model studies have shown that itraconazole is a substrate of P-glycoprotein, which is located at the blood-brain barrier and mediates efflux of itraconazole from CNS into circulation. 10 Posaconazole is a substrate and inhibitor of Pglycoprotein, but it is yet unknown whether this has an impact on posaconazole brain tissue concentrations.
At present, voriconazole should be regarded as the drug of choice in cerebral mold infections, particularly in those caused by Aspergillus species. However, Zygomycetes are typically resistant to voriconazole but frequently susceptible to posaconazole. Thus, posaconazole may be considered as an alternative or as an adjunct to liposomal amphotericin B in patients with cerebral zygomycosis, but further studies are needed to extend the limited knowledge of the CNS pharmacokinetic properties of posaconazole. Finally, recent data indicate that neurosurgical management could improve survival in patients with cerebral aspergillosis. 4 This option should also be considered in patients with cerebral infections caused by non-Aspergillus molds. 
